Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab

Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post‐treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight du...

Full description

Saved in:
Bibliographic Details
Published in:EJHaem 2024-08, Vol.5 (4), p.789-792
Main Authors: Naqvi, Syed, Shrestha, Asis, Alzubi, Marah, Alrawabdeh, Jawad, Thanendrarajan, Sharmilan, Zangari, Maurizio, Rhee, Frits, Schinke, Carolina, Al Hadidi, Samer
Format: Article
Language:English
Subjects:
Adverse events
Body mass index
Clinical trials
Diarrhea
dysgeusia
Mouth
Multiple myeloma
Patients
Quality of life
Skin
talquetamab
Taste disorders
Trends
Weight
weight loss
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Talquetamab is an approved therapy for relapsed multiple myeloma. This study examined dysgeusia and weight loss occurrences, alongside investigating symptom reversibility post‐treatment cessation. Dysgeusia was prevalent, persisting in 15% of patients. On average, patients lost 6% of their weight during treatment, with weight loss persisting in about half of the patients post‐discontinuation. Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.971